MetaCap

Biohaven (BHVN) vs Immunome (IMNM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Biohaven (BHVN) has outperformed Immunome (IMNM) over the past year, gaining 27.9% versus a loss of 15.3%. Biohaven is the larger company by market cap ($1.87 billion vs $1.85 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BHVN+27.86%IMNM-15.33%
+79%+29%-21%
Nov 21, 20251 yearNov 20, 2026
BHVN+73.63%IMNM+230.32%
+751%+329%-92%
Sep 19, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BHVN versus IMNM key metrics
MetricBHVNIMNM
Share price$12.39$15.69
Market cap$1.87B$1.85B
1-day change-9.23%-5.54%
YTD return+9.74%-26.96%
1-year return+27.86%-15.33%
5-year return—-7.54%
EPS (TTM)$-3.77$-2.63
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$6.94M
Revenue growth (YoY)—-23.23%
Net income (latest FY)$-738.82M$-212.39M
Operating margin—-3228.83%
Net margin—-3059.99%
52-week high$18.24$30.06
52-week low$8.03$15.55
Distance from 52-week high-32.07%-47.80%
Analyst consensusbuystrong_buy
Avg. price target upside+102.82%+123.90%
Average volume3.24M1.36M
Shares outstanding151.06M118.07M
Employees274267
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BHVN has outperformed IMNM by 43.2 percentage points over the past year.

About Biohaven

BHVN stock →

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity.

Health Care · Biotechnology: Pharmaceutical Preparations · 274 employees

About Immunome

IMNM stock →

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.

Health Care · Biotechnology: Pharmaceutical Preparations · 267 employees

BHVN vs IMNM FAQ

Which is bigger, Biohaven or Immunome?

Biohaven (BHVN) is larger, with a market capitalization of $1.87B compared with $1.85B for Immunome (IMNM).

Which stock has performed better over the past year, BHVN or IMNM?

BHVN returned +27.86% over the past 12 months, compared with -15.33% for IMNM (price return, excluding dividends). Past performance does not predict future results.

Are Biohaven and Immunome in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons